{
    "clinical_study": {
        "@rank": "95926", 
        "arm_group": [
            {
                "arm_group_label": "Bifidobacterium viable pharmaceutics", 
                "arm_group_type": "Experimental", 
                "description": "Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks"
            }, 
            {
                "arm_group_label": "Berberine Hydrochloride", 
                "arm_group_type": "Experimental", 
                "description": "Berberine Hydrochloride, 0.5g, 2/day, 12 weeks"
            }, 
            {
                "arm_group_label": "lifestyle counseling", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine\n      Hydrochloride on lowering glucose and delaying progress to diabetes in patients with\n      prediabetes and to detect the potential mechanism."
        }, 
        "brief_title": "Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prediabetes", 
        "condition_browse": {
            "mesh_term": [
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "detailed_description": {
            "textblock": "Gut microbiota may play an important role in patients with prediabetes. Berberine, which is\n      usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in\n      vitro and in vivo studies. Bifidobacterium, as a familiar probiotics, can modulate gut\n      microbiota and improve glucose and lipid metabolism in animal experiments. Therefore, the\n      aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine\n      Hydrochloride on lowering glucose and delaying progress to diabetes in patients with\n      prediabetes and to detect the potential mechanism."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any trial-related activities\n\n          -  Male or female between 18 and 70 years of age\n\n          -  19\u2264Body mass index(BMI)\u226430kg/m2\n\n          -  No participate in any clinical trial at least 3 months\n\n          -  Fasting blood glucose(FBG)<7.0mmol/L and 2-hour postprandial blood\n             glucose(2hPBG)<11.1mmol/L\n\n          -  Females in child-bearing period should be given birth control\n\n          -  No severe disease about heart, lung and kidney\n\n          -  Ability and willingness to adhere to the protocol including performance of\n             self-monitored blood glucose (SMBG) profiles according to the protocol;\n\n          -  Subject is likely to comply with the Investigators instruction.\n\n        Exclusion Criteria:\n\n          -  Type 2 diabetes mellitus or type 1 diabetes mellitus\n\n          -  Females of childbearing potential who are pregnant\uff0cbreastfeeding or intend to become\n             pregnant or are not using adequate contraceptive methods\n\n          -  Impaired liver function, defined as Aspartate aminotransferase(AST) or Alanine\n             transaminase(ALT)> 2 times upper limit of normal (central laboratory)\n\n          -  Impaired renal function, defined as serum-creatinine\u2265133\u03bcmol/L\n\n          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure\u2265160mmHg\n             and /or diastolic blood pressure\u226595mmHg)\n\n          -  Chronic gastrointestinal diseases\n\n          -  Cancer and medical history of cancer (except basal cell skin cancer or squamous cell\n             skin cancer)\n\n          -  Any clinically significant disease or disorder, which in the Investigator's opinion\n             could interfere with the results of the trial\n\n          -  Mental incapacity, psychiatric disorder, unwillingness or language barriers\n             precluding adequate understanding or co-operation, including subjects not able to\n             read and write\n\n          -  Previous participation in this trial. Participation is defined as randomized.\n             Re-screening of screening failures is allowed only once within the limits of the\n             recruitment period\n\n          -  Known or suspected hypersensitivity to trial products or related products\n\n          -  Known or suspected abuse of alcohol, narcotics or illicit drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02082756", 
            "org_study_id": "2013KTZB03-02-01B"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bifidobacterium viable pharmaceutics", 
                "intervention_name": "Bifidobacterium viable pharmaceutics", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Berberine Hydrochloride", 
                "intervention_name": "Berberine Hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prediabetes", 
            "Berberine Hydrochloride", 
            "Bifidobacterium"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Xuan Xie, Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shaanxi", 
                        "zip": "710004"
                    }, 
                    "name": "Second Affiliated Hospital of Xi'an Jiaotong University"
                }, 
                "investigator": {
                    "last_name": "Xuan Xie, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "YangWei Wang, Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shaanxi", 
                        "zip": "710068"
                    }, 
                    "name": "Shaanxi Provincial People's Hospital"
                }, 
                "investigator": {
                    "last_name": "YangWei Wang, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "PeiJun Mao, Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shaanxi", 
                        "zip": "710054"
                    }, 
                    "name": "The 323rd Hospital of People's Liberation Army"
                }, 
                "investigator": {
                    "last_name": "PeiJun Mao, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "BingYin Shi, Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an,", 
                        "country": "China", 
                        "state": "Shaanxi", 
                        "zip": "710061"
                    }, 
                    "name": "First Affiliated Hospital of Xi'an Jiaotong University"
                }, 
                "investigator": {
                    "last_name": "BingYin Shi, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment\uff1aan Open-label, Multicenter\uff0cRandomized, Prospective\uff0cControlled Study", 
        "overall_contact": {
            "email": "qiuheji@hotmail.com", 
            "last_name": "Qiuhe Ji, Ph.D.,M.D."
        }, 
        "overall_contact_backup": {
            "email": "mingjie1207@163.com", 
            "last_name": "Jie Ming, M.D."
        }, 
        "overall_official": {
            "affiliation": "Department of Endocrinology, Xijing Hospital, Fourth Military Medical University", 
            "last_name": "Qiu Ji, Ph.D..M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "2-hour postprandial blood glucose are measured at baseline and week 12 during a 2 hour-meal test.", 
            "measure": "Change in 2-hour postprandial blood glucose between baseline to week 12", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02082756"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Faecal bacterial composition determined from microbiological cultures and deep metagenomic next-generation sequencing of bacterial DNA in feces.", 
                "measure": "Gut microbiome composition", 
                "safety_issue": "No", 
                "time_frame": "Baseline and week 12"
            }, 
            {
                "description": "Standardized questionaries regarding gastrointestinal function are filled out at each study visit (0, 4, 8 and 12 weeks after randomization) to detect possible adverse effects of antibiotics. In addition, subjects are given a calendar and informed to write down any symptom or illness during the study period.", 
                "measure": "Adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to week 12"
            }
        ], 
        "source": "Xijing Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xijing Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}